CYRX vs MCK
CYRX: Cryoport is the leading provider of end-to-end temperature-controlled supply chain solutions specifically built for cell and gene therapies, from preclinical development through global commercialization. MCK: McKesson is a healthcare services giant that orchestrates the entire pharmaceutical and medical supply chain—from drug distribution and specialty oncology care to technology platforms that connect patients, pharmacies, and providers.
Side-by-side fundamentals
| Metric | CYRX | MCK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.42 | $814.04 | |
| Market cap as of 2026-07-23 | $838M | $96.6B | |
| P/E as of 2026-07-23 | 11.02 | 20.29 | CYRX lower |
| PEG as of 2026-07-23 | n/a | 1.50 | |
| Net margin as of 2026-07-23 | +41.6% | +1.2% | CYRX higher |
| Gross margin as of 2026-07-23 | +47.2% | +3.6% | CYRX higher |
| Operating margin as of 2026-07-23 | -21.4% | +1.5% | MCK higher |
| ROE as of 2026-07-23 | +15.0% | +39.4% | MCK higher |
| ROA as of 2026-07-23 | +9.9% | +5.7% | CYRX higher |
| Debt / equity as of 2026-07-23 | 0.38 | 1.29 | CYRX lower |
| Revenue growth (YoY) as of 2026-07-23 | -14.8% | +12.4% | MCK higher |
| Revenue CAGR (3y) SEC XBRL | -9.4% | +13.4% | MCK higher |
| Dividend yield as of 2026-07-23 | n/a | +0.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.89 | 0.32 | |
| 1-year return as of 2026-07-22 close | +121.0% | +14.7% | CYRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.